Genedrive Plc
Genedrive plc is a Manchester-based biotechnology company focused on developing point-of-care molecular diagnostics. Their mission is to design easy-to-use tests that improve clinical outcomes in time-critical settings. They have developed tests for antibiotic-induced hearing loss, hepatitis C, and pathogen detection, among others. The company aims to become a leader in decentralized molecular diagnostics, with applications in healthcare, military, and other sectors. They are committed to sustainability, including achieving Net Zero emissions by 2050, and adhere to high standards of corporate governance and ethical conduct.
Industries
Nr. of Employees
small (1-50)
Genedrive Plc
48 Grafton Street, Manchester, M13 9XX, UK
Products
Point-of-care pharmacogenetic test for metaboliser status
A rapid point-of-care pharmacogenetic assay to determine patient metaboliser status for time-critical therapeutic decisions.
Point-of-care genetic test to identify aminoglycoside hearing-loss risk
A point-of-care genetic assay to identify patients at elevated risk of aminoglycoside-induced hearing loss for use in neonatal and time-critical care.
Point-of-care genotyping and molecular diagnostics system
A compact molecular diagnostics instrument designed to perform genotyping and sequence-analysis-based assays at or near the point of need.
Point-of-care pharmacogenetic test for metaboliser status
A rapid point-of-care pharmacogenetic assay to determine patient metaboliser status for time-critical therapeutic decisions.
Point-of-care genetic test to identify aminoglycoside hearing-loss risk
A point-of-care genetic assay to identify patients at elevated risk of aminoglycoside-induced hearing loss for use in neonatal and time-critical care.
Point-of-care genotyping and molecular diagnostics system
A compact molecular diagnostics instrument designed to perform genotyping and sequence-analysis-based assays at or near the point of need.
Services
Development and iterative refinement of point-of-care molecular assays and associated workflows for clinical use.
Support for regulatory submissions and conformity activities for in vitro diagnostic devices, including CE/IVDR processes and other regulator interactions.
Support for clinical evaluation and deployment of point-of-care tests in healthcare settings, including participation in NHS trials and emergency-care evaluations.
Establishment and management of distributor relationships and attendance at industry events to support market access and product demonstrations.
Development and iterative refinement of point-of-care molecular assays and associated workflows for clinical use.
Support for regulatory submissions and conformity activities for in vitro diagnostic devices, including CE/IVDR processes and other regulator interactions.
Support for clinical evaluation and deployment of point-of-care tests in healthcare settings, including participation in NHS trials and emergency-care evaluations.
Establishment and management of distributor relationships and attendance at industry events to support market access and product demonstrations.
Expertise Areas
- Point-of-care molecular diagnostics
- Pharmacogenomics (pharmacogenetic test development)
- Assay development and analytical validation
- Clinical implementation in emergency medicine
Key Technologies
- Real-time DNA amplification
- Point-of-care (POC) molecular testing platforms
- Genotyping and sequence analysis
- Assay control and quality kit development
News & Updates
Exhibition at the UK Stroke Forum Conference in Liverpool from 3rd to 5th December 2024.
Exhibition at the 2nd POCT for Scotland in Glasgow on 14th November 2024.
Exhibition at Medica 2024 in Hall 1 stand F09-1 from 11th to 14th November 2024.
Exhibition at the UK Stroke Forum Conference in Liverpool from 3rd to 5th December 2024.
Exhibition at the 2nd POCT for Scotland in Glasgow on 14th November 2024.
Exhibition at Medica 2024 in Hall 1 stand F09-1 from 11th to 14th November 2024.